Esperion to Hold Conference Call to Provide Update On Findings From Study of ETC-216
November 03 2003 - 10:45PM
PR Newswire (US)
Esperion to Hold Conference Call to Provide Update On Findings From
Study of ETC-216 ANN ARBOR, Michigan, November 4 /PRNewswire/ --
Call Scheduled for Tuesday, November 4, 2003 at 4:30 P.M. Will
Detail Findings Related to Study of HDL Therapy in Treatment of
Atherosclerosis Esperion Therapeutics, Inc. will hold a conference
call to provide detailed findings related to the Company's Phase 2
clinical trial for ETC-216 for the treatment of atherosclerosis.
The call is scheduled for Tuesday, November 4, 2003 at 4:30 PM and
will be led by Roger S. Newton, Ph.D., President and CEO of
Esperion. In initial study results presented in June 2003, the
Company announced that ETC-216 demonstrated statistically
significant reduction in percent atherosclerotic plaque volume
among acute coronary syndrome patients. The Company as well as the
study's principal investigator, Steven E. Nissen, M.D., F.A.C.C.,
medical director of the Cleveland Clinic Cardiovascular
Coordinating Centre, continue to confirm the positive results of
the study, which showed for the first time that ETC-216 is able to
reverse the course of atherosclerotic disease in acute coronary
syndrome patients at the end of six weeks. The full data from the
study have not been released and remain under embargo until 4:00
p.m. on Tuesday, November 4. Esperion continues to honour the
publication embargo and will not comment on rumours or assumptions
related to the full data set until after the embargo has been
lifted in accordance with standard accepted practices related to
publication of data in a peer-reviewed setting. What: Esperion
Conference Call on ETC-216 Study Findings When: Tuesday, November
4, 2003 at 4:30 p.m. (ET) Via Telephone: From U.S. and Canada, dial
(800) 901-5226 From other locations, dial +1 (617) 786-4513 All
callers should give the conference ID "Esperion" when prompted Via
Internet: Visit http://www.esperion.com, click on the Investor
Relations link, and then click on the Calendar link shortly before
4:30 p.m. (ET) A replay of the Esperion conference call will be
available beginning at 8:00 p.m. (ET) on November 4, 2003 until
11:59 p.m. (ET) on November 11, 2003. To access the replay from the
U.S. and Canada, dial (888) 286-8010 and enter passcode number
92056812. From all other locations, dial +1 (617) 801-6888 and
enter passcode number 92056812. To access the replay via the
Internet, visit http://www.esperion.com, click on the Investor
Relations link, and then click on the Audio/Visual Archives link.
Esperion Therapeutics Esperion Therapeutics, Inc. discovers and
develops pharmaceutical products for the treatment of
cardiovascular disease. Esperion intends to commercialise a novel
class of drugs that focuses on a new treatment approach called "HDL
Therapy," which is based on the Company's understanding of
high-density lipoprotein, or HDL, function. HDL is the primary
facilitator of the RLT pathway by which excess cholesterol and
other lipids are removed from arteries and other tissues and are
transported to the liver for elimination from the body. Esperion's
goal is to develop drugs that exploit the beneficial functions of
HDL within the RLT pathway. Esperion currently has four product
candidates in clinical development. Esperion is listed on the
Nasdaq National Market under the symbol "ESPR." For more
information, visit http://www.esperion.com. Safe Harbor Statement
The information contained in this press release includes
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are often identified by words such as "hope," "may,"
"believe," "anticipate," "plan," "expect," "require," "intend,"
"assume" and similar expressions. Forward-looking statements speak
only as of the date of this press release, reflect management's
current expectations, estimations and projections and involve
certain factors, such as risks and uncertainties, that may cause
actual results, performance or achievements to be far different
from those suggested by the Company's forward-looking statements.
These factors include, but are not limited to, risks associated
with: the Company's ability to successfully execute its business
strategies, including entering into strategic partnerships or other
transactions; the progress and cost of development of the Company's
product candidates; the extent and timing of market acceptance of
new products developed by the Company or its competitors; the
Company's dependence on third parties to conduct clinical trials
for the Company's product candidates; the extent and timing of
regulatory approval, as desired or required, for the Company's
product candidates; the Company's dependence on licensing
arrangements and strategic relationships with third parties;
clinical trials; manufacturing; the Company's dependence on patents
and proprietary rights; litigation, proceedings, investigations and
other disruptions of management's time resulting from the
acquisition of the Company's common stock by various persons
associated with Scott Sacane; the procurement, maintenance,
enforcement and defence of the Company's patents and proprietary
rights; competitive conditions in the industry; business cycles
affecting the markets in which any of the Company's future products
may be sold; extraordinary events and transactions; seeking and
consummating business acquisitions, including the diversion of
management's attention to the assimilation of the operations and
personnel of any acquired business; the timing and extent of the
Company's financing needs and the Company's access to funding,
including through the equity market, particularly in light of the
impact on the market value of the Company's common stock of matters
outside of the Company's control, such as trading activities by
third parties; fluctuations in foreign exchange rates; and economic
conditions generally or in various geographic areas. Because all of
the foregoing factors are difficult to forecast, you should not
place undue reliance on any forward-looking statement. More
detailed information about some of these and other risk factors is
set forth in the Company's filings with the Securities and Exchange
Commission. The Company does not intend to update any of these
factors or to publicly announce the results of any revisions to any
of these forward-looking statements other than as required under
the federal securities laws. Company Amy Cannon Contact: Manager,
Corporate Communications Esperion Therapeutics, Inc. +1 (734)
222-1801 acannon@esperion.com Media Jim Wetmore Contact: Berry
& Company Public Relations +1 (212) 253-8881
jwetmore@berrypr.com /CONTACT: Amy Cannon, Manager, Corporate
Communications of Esperion Therapeutics, Inc., +1-734-222-1801,
acannon@esperion.com; or Jim Wetmore of Berry & Company Public,
+1-212-253-8881, jwetmore@berrypr.com, for Esperion Therapeutics,
Inc./ /Web site: http://www.esperion.com / (ESPR)
Copyright